deltatrials
Completed PHASE2 NCT00004990

Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis

Pulse Dexamethasone in Focal Segmental Glomerulosclerosis

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Glomerulonephritis Nephrotic Syndrome
Interventions Dexamethasone
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Mar 31, 2000 Completion: Dec 31, 2004

A PHASE2 clinical study on Glomerulonephritis and Nephrotic Syndrome, this trial is completed. The trial is conducted by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and has accumulated 5 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States